then interacts with several other cytoplasmic proteins containing SH2 domains, including phospholipase C, ras GTPase activating protein, phosphatidyl-inositol 3-kinase (PI3-K), members of the pp60src family of protein tyrosine kinase, tyrosine phosphatase SHP-2 and the Janus kinase/signal transducers and activators of transcription pathway. 1, 11 Mutant mice expressing a PDGFR-␤ that can no longer activate PI3-K or phospholipase C-␥ exhibit attenuated PDGFdependent cellular functions but no reduction in survival. 12 Second messengers include inositol-1,4,5-triphosphate and diacylglycerol; intracellular calcium release; protein kinase C-␣, -␤, -, and -; and prenylated, low molecular weight G proteins. 1,13,14 Mitogen-activated protein kinase (MAPK) is a downstream target of PI3-K. 15 Different MAPK, such as extracellular signal-regulated kinase, cJun N-terminal kinase, and p38, mediate different effector functions in MC, such as proliferation and TGF-␤ or chemokine synthesis in response to PDGF. 16 Inhibition of extracellular signal-regulated kinase in vivo indeed ameliorated mesangioproliferative nephritis. 17 PDGF-BB and angiotensin II (AngII) differ in their potency and duration of activation of the MAPK cascade, which may explain why PDGF-BB is a potent mitogen for MC, whereas AngII triggers only cell hypertrophy. 18 In the nucleus, PDGF signaling activates various proto-oncogenes and immediate early response genes, including c-fos, JunB, c-myc, and egr-1, 19, 20 that are effectors of the receptor tyrosine kinase and responsible for particular downstream functions. 21 Homodimeric ␣␣ and ␤␤ receptor complexes induce overlapping but distinctly different effects on target cells, which might be explained by differential interactions with various SH2 domain proteins. Autophosphorylation on different tyrosine residues might explain the unique properties of the heterodimeric ␣␤ receptor complex in comparison with homodimeric receptors. Finally, PDGF signaling can also be modulated in the extracellular milieu by matrix molecules. Naturally occurring PDGF antagonists include secreted, truncated receptor forms and ␣ 2 -macroglobulin. 1 The extracellular secreted protein, acidic and rich in cysteine binds PDGF-AB and -BB and thereby favors PDGF-AA bioactivity. 3 
STUDIES IN RENAL CELLS IN VITRO
In general, PDGF are major autocrine or paracrine mitogens and survival factors in many cells of mesenchymal origin. 10,22-27 PDGF synthesis is induced in cultured MC by various mediators, including PDGF itself, EGF, basic fibroblast growth factor, TNF-␣, TGF-␤, AngII, endothelin, thrombin, lipoproteins, lysophosphatidylcholine, phospholipids, and CpG nucleotides. 4,28 -30 Many mitogens in fact exert their mitogenic effect through the induction of PDGF. 31, 32 Negative regulators of PDGF synthesis have also been identified and include platelet factor-4 and NOV/ CCN3. 33, 34 In glomerular endothelial cells, hypoxia is another inducer of PDGF-B chain synthesis, whereas shear stress reduces it. 35, 36 In proximal tubular cells, hyperglycemia is a strong stimulus for PDGF. 37 In these cells, growth factors such as hepatocyte growth factor and TGF-␤, which are ultrafiltered in the glomerulus, may also act as PDGF inducers. 38 Stimulation of MC with different PDGF ligands results in cellular proliferation and migration. In general, PDGF-AA exerts at best weak effects on MC proliferation. 39, 40 In metanephric mesenchymal cells, PDGF-AA causes modest cell migration but has no effect on DNA synthesis. 41 In contrast, PDGF-BB stimulation of MC induces a rapid mobilization of intracellular calcium, decreases p27, and increases cyclin A and CDK2, resulting in pronounced cell proliferation. 39, 40, 42, 43 MC migration in response to PDGF-BB involves upregulation of the cytoskeletal proteins moesin and radixin. 44 MC proliferation can also be induced by PDGF-CC and -DD. 9, 25 In 3D culture, the MC responsiveness to PDGF decreases markedly as a result of PDGFR downregulation. 40 Mitogenic PDGF effects on other renal cell types are less consistent. PDGF does not affect proliferation in glomerular endothelial cells. 45 Tubular epithelial cells exhibit variable responses, 46,47 and papillary renal fibroblasts and to a lesser extent cortical fibroblasts respond with mitogenesis. 48 PDGF also induce extracellular matrix synthesis in MC, parietal epithelial cells, and, to a lesser degree, tubular epithelial cells. 49 -53 They may affect this by acting upstream of and/or in con- cert with other cytokines such as TGF-␤. 52, 54, 55 In contrast to TGF-␤, PDGF exhibits little effect on matrix degradation. 56, 57 PDGF-BB stimulation of MC leads to an increased expression of numerous mediators of disease and inflammation, including TGF-␤1, CCL-2, CXC3CL1, plasminogen activator inhibitor-1, IL-6, endothelin-1, inducible nitric oxide synthase, and YB-1. 4,16,58 -61 Through effects on MC contraction and prostanoid production, PDGF also contributes to the regulation of glomerular hemodynamics. Infusion of PDGF into isolated microperfused glomeruli increases intraglomerular pressure and vascular resistance and decreases flow rate. [62] [63] [64] Finally, PDGF affects very-low-conductance Ca 2ϩ -permeable channels, 65-67 which regulate intracellular calcium and thereby prevent apoptosis in MC, 68 as well as the permeability of intercellular tight and gap junctions in tubular cells and MC, respectively. 69,70 These latter effects may also contribute to the increased tissue permeability that is a characteristic of several kidney diseases.
NORMAL DISTRIBUTION IN EMBRYONIC AND ADULT RODENT AND HUMAN KIDNEY
Early in metanephric kidney development, PDGFR-␣ and -␤ are expressed in the undifferentiated blastema, vascular structures (PDGFR-␤ only), and interstitium. 71,72 mRNA encoding PDGFR-␣ is present in some mesangial structures in early glomeruli but is largely lost as glomeruli mature. 72 During the transition from S-phase vesicles to identifiable glomeruli, PDGFR-␤ is expressed uniformly by cells differentiating into MC. 72 In developing metanephric kidney, PDGF-B chain is expressed by the differentiating epithelium of early-stage glomerular vesicles (comma and S stage), but in later stages of glomerular development, the expression of PDGF-B chain is limited to MC. 72 PDGF-D expression has been identified in the epithelial cells of comma-and S-shaped vesicles and in the visceral epithelial cells of later stage glomeruli in developing human kidneys. 73 The localization of PDGF-A and -B and PDGFR-␣ and -␤ in postnatal human and rodent kidneys has been well established (Table 1) . PDGFR-␣ is widely expressed by renal interstitial cells and to some degree by MC. 71 Constitutive PDGFR-␣ expression by smooth muscle cells of the renal arterial vasculature has been identified but is not uniform among these cells. PDGFR-␤ is expressed postnatally by MC, glomerular parietal epithelial cells, and interstitial cells. 74 Figure 2. Immunohistochemical localization of PDGF-D and its receptor PDGFR-␤ and of PDGF-C and its principle receptor PDGFR-␣ in human (A through D), mouse (E through H), and rat (I through K) glomeruli. Constitutive expression of PDGF-D is localized to podocytes in humans and MC in mice and is not detected in rat glomeruli. VSMC in all of these species express PDGF-D (E and I). PDGFR-␤ is expressed by MC and interstitial cells in all of these species. Expression of PDGFR-␤ by parietal epithelial cells is best seen in the human (B). PDGF-C is constitutively expressed in mouse MC and by microvascular endothelial cells in all three species. Although not visualized in this preparation, expression of PDGF-C by parietal epithelial cells has been reported. PDGFR-␣ is not normally detectable in human or mouse glomeruli but is expressed by interstitial cells. Studies of PDGFR-␣ expression in normal adult rat glomeruli are not available.
BRIEF REVIEW www.jasn.org PDGF-A chain is normally expressed by mature podocytes and epithelial cells of the distal nephron, including collecting ductal cells and urothelium. 75 In the mouse, PDGF-A chain also seems to be expressed by cells of the loop of Henle. 76 Although low levels of PDGF-B chain expression by MC in normal mature glomeruli may be present, it has been difficult to detect constitutive expression by these cells using immunohistochemistry.
Localization of the more newly recognized PDGF isoforms has been hampered by the limited availability of reliable reagents. Important differences in patterns of expression in mouse, rodent, and human kidneys have been revealed ( Figure 2 , Table 1 ). PDGF-C has been localized to arterial smooth muscle cells and collecting duct epithelial cells in the rat. In humans, PDGF-C has been localized to parietal epithelial cells in the glomerulus, tubular cells from all parts of the nephron distal to the proximal tubules, and arterial endothelial cells. 25, 77 In normal human adult kidneys, PDGF-D expression persists in podocytes and is constitutively expressed by vascular smooth muscle cells (VSMC). 73 Constitutive expression of PDGF-D in the rat is limited to VSMC only. 26 In the mouse, PDGF-D is constitutively expressed in glomeruli but by MC and not podocytes in contrast to humans. 78 
INSIGHT INTO RENAL DEVELOPMENT OBTAINED FROM GENETICALLY ALTERED MICE
Genetically altered mice can provide important clues to the developmental role of individual proteins and can provide clues to pathogenetic processes during renal disease in adult animals. PDGF-A Ϫ/Ϫ mice usually die on embryonic day 10. Postnatally, surviving mice develop lung emphysema but no renal abnormalities. 79 PDGF-C Ϫ/Ϫ mice have been reported to die in the perinatal period and exhibit a complete cleft of the secondary palate. 6 Mice with combined homozygous deficiency for PDGF-A and -C among other defects lack elements of the renal cortical interstitium and largely seem to mirror the phenotype of mice deficient for PDGFR-␣. 80 These observations point to potential roles of PDGF-A and -C and/or PDGFR-␣ in mediating renal interstitial disease, a notion that was recently confirmed by us (see Intervention Studies).
Mice deficient for PDGF-B also die perinatally. The most notable abnormality is an absence of normal glomerular tuft formation as a result of a complete lack of MC migration into the glomerular stalk, whereas glomerular endothelial cells, the basement membrane, and podocytes are largely preserved. Most PDGF-B mutant embryos also develop fatal hemorrhages as a result of disturbed arterial pericyte formation and function. [81] [82] [83] An almost identical renal phenotype results from genetic ablation of PDGF-B in endothelial cells only, 84 in PDGFR-␤-deficient mice, 85 or when an antagonistic anti-PDGFR-␤ mAb was administered to neonatal mice, where outer cortical glomeruli still form after birth. 86 Finally, when the matrix retention motif within the PDGF-B molecule was deleted in mice, delayed formation of the mesangium was again noted and resulted in proteinuria and glomerulosclerosis. 87 Whereas PDGF-D null mice have not been described yet, its overexpression using a metallothionein promoter resulted in no gross pathologic renal changes on embryonic day 15, but no live transgenics were born (W. LaRochelle, PhD, and M.J. Jeffers, PhD, Curagen Corp., Branford, CT, personal communication, February 27, 2007). When we specifically overexpressed PDGF-D in podocytes of mice, intraglomerular pathology ranging from mesangioproliferative lesions to crescentic glomerulonephritis evolved. 88 Collectively, these observations point to central and nonredundant roles of PDGF-B and -D and PDGFR-␤ in the development of the glomerular mesangium. The effects of PDGF-B and, by implication, PDGF-D and PDGFR-␤ interactions that allow development of a mesangium are recapit- 
EXPRESSION OF PDGF AND PDGFR IN RENAL DISEASE
Upregulated PDGF expression has been observed in a large number of rodent injury models, including mesangioproliferative anti-Thy 1.1 glomerulonephritis, AngII-induced renal damage, nephrotoxic nephritis, puromycin-induced FSGS, diabetic nephropathy, renal transplantation, ischemia/ reperfusion, murine lupus nephritis, and murine IgA nephropathy. Studies examining the PDGF expression in human renal tissues have focused on a similar spectrum of renal diseases (Table 2) .
PDGF-A was overexpressed within MC in models of mesangioproliferative glomerulonephritis and within endothelial and smooth muscle cells during human vascular transplant rejection. 90, 91 In animal models, PDGF-C was upregulated in MC and podocytes upon cellular injury and/or activation and within the interstitium at sites of renal fibrosis. 25 In human renal biopsies, PDGF-C overexpression was prominent in podocytes of membranous nephropathy as well as transplant glomerulopathy and again at sites of interstitial fibrosis. 77 An upregulation of PDGFR-␣ has been shown in VSMC and in tubulointerstitial cells in the course of different renal diseases. 78, 92 Numerous publications have reported an overexpression of PDGF-B in the course of renal diseases. Upregulation of PDGF-B has been reported in MC, VSMC, tubular cells, interstitial cells, and, in rare instances, podocytes in animal models and human renal diseases (Table 2) a Expression in comparison with normal kidney: ϩ/Ϫ, limited to a few models/diseases or controversial results; ϩ, upregulation. Empty boxes denote lack of data or no change in expression from normal (see Table 1 ). b Cell type not specified.
OVEREXPRESSION OR PHARMACOLOGIC ADMINISTRATION
Various studies have investigated the renal consequences of infusing or overexpressing the different PDGF isoforms in vivo. Infusion of even very high dosages of PDGF-AA (5 mg/kg) into healthy rats failed to induce renal pathology. 103 Similarly, adenoviral transfection of mouse liver with a construct encoding PDGF-C and causing elevated circulating levels of this isoform did not induce renal abnormalities. 104 A novel biologic role of PDGF-C, which has yet to be explored in the kidney, is a very potent induction of angiogenesis. 105 Infusion of recombinant PDGF-BB into healthy rats led to a selective increase of glomerular MC proliferation. 106 PDGFinduced MC proliferation and mesangial matrix accumulation were markedly augmented when the MC had suffered a minor (subclinical) injury before the PDGF infusion. 106 Administration of PDGF-BB to hyperglycemic GK rats also resulted in acute, transient MC proliferation and activation. 107 The induction of mesangioproliferative changes was reproduced in healthy mice and rats by hepatic transfection with viral constructs encoding PDGF-B, resulting in elevated circulating levels of this isoform. 104 Finally, glomerular overexpression of PDGF-B also drove bone marrow-derived cells toward a mesangial-like phenotype in vivo. 108 At very high dosages (5 mg/kg), PDGF-BB infusion into rats induced dosage-dependent renal tubulointerstitial cell proliferation, myofibroblast formation, and fibrosis, which were reversible after PDGF-BB infusion was abrogated. 103 Mice with high circulating levels of PDGF-D after adenoviral transfection of the liver developed a severe mesangioproliferative glomerulopathy, characterized by enlarged glomeruli and a striking increase in glomerular cellularity. 104 Collectively, these data demonstrate potent roles of PDGF-B and -D in inducing mesangioproliferative changes as well as tubulointerstitial fibrosis in the case of PDGF-B.
INTERVENTION STUDIES
Little is known on the effects of PDGF-A inhibition in vivo (Table 3) . PDGF-A chain antisense oligonucleotides improved arterial and renal damage in stroke-prone spontaneously hypertensive rats. 109 Antagonism of PDGF-C using a neutralizing antiserum reduced the extent of renal tubulointerstitial fibrosis after unilateral ureter ligation. 110 These studies complement other studies in which cardiac overexpression of PDGF-C induced myocardial fibrosis. 111 Various interventions that reduce MC proliferation in vivo, such as administration of heparin, C-type natriuretic peptide, or antisense oligonucleotides against Egr-1, may act indirectly through inhibition of autostimulatory effects of endogenously produced PDGF. Each of BRIEF REVIEW www.jasn.org these interventions also led to reduced glomerular expression of PDGF-B chain. [112] [113] [114] Similarly, aminoguanidine reduced glomerular PDGF-B overexpression and matrix accumulation in streptozotocin-induced rodent diabetes. 115 A number of specific interventions aimed at neutralizing PDGF-B or -D or blocking the PDGF-␤ receptor have been shown to reduce MC proliferation and matrix accumulation in rat anti-Thy 1.1 mesangioproliferative glomerulonephritis (Table 3) , 26,116 -119 whereas glomerular endothelial cell proliferation was not affected. 120 PDGF-B antagonism in this model did not affect the TGF-␤ system, suggesting that PDGF-B acts downstream or independent of TGF-␤ and may thus be a specific target to ameliorate both increased cellularity and matrix production. 121 More important, transient PDGF-B or -D antagonism during the mesangioproliferative phase of progressive anti-Thy 1.1 glomerulonephritis prevented the subsequent development of renal failure and glomerular as well as tubulointerstitial scarring. 122, 123 Beneficial effects of anti-PDGF-D treatment were observed even when treatment started after the acute mesangioproliferative phase, suggesting that PDGF-D antagonism also has a role in retarding tubulointerstitial fibrosis. 124 A role for PDGF-D in fibrotic disease is also suggested by the finding of cardiac fibrosis after heart-specific overexpression. 111 Trapidil, a nonspecific PDGF antagonist, markedly reduced PDGF-BB-induced proliferation of MC in vitro 125 and in vivo 126 ; however, in rabbit accelerated nephrotoxic nephritis and in rats with renal ischemia/reperfusion injury, clinical and histologic data worsened in trapidil-treated animals. 97, 127 Other drugs that are used in patients with renal disease, including calcium channel blockers, lovastatin, and ramipril, also interfere with PDGF signaling, but it is unknown whether the beneficial effect of these drugs may be partly due to PDGF inhibition. 128 -130 A number of low molecular weight PDGF receptor tyrosine kinase blockers have been evaluated in renal disease (Table 3). Some caution is necessary when interpreting these studies, because many of the kinase blockers exhibit only relative specificity for the PDGF receptor, and some, such as the c-abl kinase inhibitor imatinib (STI 571), were developed primarily to inhibit other kinases and only reduce PDGFR-␣ and -␤ signaling as a "side effect." Ki6896, like trapidil, worsened rat renal ischemia/reperfusion injury. 97 In contrast, in all other injury models tested, blockade of the PDGFR tyrosine kinase was beneficial. Thus, imatinib reduced mesangioproliferative changes in experimental glomerulonephritis 131, 132 ; mildly ameliorated both renal functional and structural parameters in diabetic apolipoprotein E knockout mice 133 ; improved survival, renal function, and histology in murine lupus 134 ; and prevented chronic allograft nephropathy after rat kidney transplantation. 135 Finally, another PDGF tyrosine kinase inhibitor, AG 1295, mildly delayed the development of interstitial fibrosis in rats with unilateral ureteral obstruction 136 ; however, at least in the case of imatinib, it is not always clear whether the benefit observed related to inhibition of the PDGFR tyrosine kinase or to inhibition of the c-abl kinase, which also contributes to renal interstitial fibrosis. 137 In addition, significant adverse effects of imatinib on the myocardium have been related to inhibition of the cabl kinase rather than the PDGFR tyrosine kinase. 138 Taken together, these data provide strong evidence that inhibition of PDGF-B and -D can be an effective approach to proliferative glomerulonephritis and that both can also directly or indirectly affect the progression of renal tubulointerstitial damage. Recent evidence also suggests a beneficial effect of PDGF-C antagonism in the latter process. 110 At least two studies suggested that PDGF inhibition should be avoided in instances of ischemia-reperfusion injury of renal tubules. 97 Although the potential benefits of PDGF blockade in human renal disease is not yet known, it is noteworthy that specific inhibition of PDGFR-␤ in normal volunteers so far has shown a good safety profile, whereas in some patients with tumors, fluid retention and ascites has been noted. 139 
CONCLUSIONS
From the wealth of data discussed, it is obvious that PDGF is one of the bestcharacterized growth factor systems in renal disease. Altered expression of PDGF and/or its receptors is involved in most renal diseases and is an essential component of mesangial and interstitial proliferation and responses to injury. Specific anti-PDGF interventions can prevent important long-term sequelae in experimental models of renal disease. An obvious first human disease to test anti-PDGF therapy is mesangioproliferative glomerulonephritis, in particular IgA nephropathy. Specific anti-PDGF compounds have been developed and tested in humans, including CDP860, a humanized, PEGylated di-FabЈ that blocks the PDGFR-␤, and CR002, a fully human mAb to PDGF-D. 139, 140 Clearly, the time is ready for clinical trials of PDGF intervention. Imatinib, already approved for human use as an antineoplastic agent, is a candidate therapeutic agent for this purpose, but later generation tyrosine kinase inhibitors are being tested for potentially better safety profiles.
Which research areas merit further studies in this field? Effects of anti-PDGF therapy in other renal diseases, in particular diabetic nephropathy and lupus nephritis, have not been well characterized so far. Another field that has received little attention is the regulation of PDGF bioactivity in renal disease. We have characterized a PDGF-regulated downstream antagonist, NOV/CCN3, 34 and others may exist and be useful targets for pharmacologic intervention. Uncharted territory also relates to the proteolytic activation of the novel PDGF-C and -D isoforms in renal disease as well as the role of matrix binding of PDGF in the kidney. Finally, novel activities such as the angiogenic properties of PDGF-CC may merit exploitation in models of thrombotic microangiopathy. 
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